In vitro inhibition of human nucleoside transporters and uptake of azacitidine by an isocitrate dehydrogenase-2 inhibitor enasidenib and its metabolite AGI-16903

References

• Amatangelo MD, Quek L, Shih A, et al. (2017). Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood 130:732–41.
   PubMed Web of Science ®Google Scholar
• Anders NM, Liu J, Wanjiku T, et al. (2016). Simultaneous quantitative determination of 5-aza-2'-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci 1022:38–45.
   PubMed Web of Science ®Google Scholar
• Chowdhury R, Yeoh KK, Tian YM, et al. (2011). The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463–9.
   PubMed Web of Science ®Google Scholar
• Damaraju VL, Mowles D, Yao S, NG, A, et al. (2012). Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 31:236–55.
   PubMed Web of Science ®Google Scholar
• Dang L, Jin S, Su SM. (2010). IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 16:387–97.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–44.
   PubMed Web of Science ®Google Scholar
• Derissen EJ, Hillebrand MJ, Rosing H, et al. (2014). Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry. J Pharm Biomed Anal 90:7–14.
   PubMed Web of Science ®Google Scholar
• Dombret H, Raffoux E, Gardin C. (2008). Acute myeloid leukemia in the elderly. Semin Oncol 35:430–8.
   PubMed Web of Science ®Google Scholar
• Dombret H, Seymour JF, Butrym A, et al. (2015). International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291–9.
   PubMed Web of Science ®Google Scholar
• Farrell JJ, Elsaleh H, Garcia M, et al. (2009). Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187–95.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. (2010). Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562–9.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–67.
   PubMed Web of Science ®Google Scholar
• Hummel-Eisenbeiss J, Hascher A, Hals PA, et al. (2013). The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Mol Pharmacol 84:438–50.
   PubMed Web of Science ®Google Scholar
• Issa JP, Kantarjian HM. (2009). Targeting DNA methylation. Clin Cancer Res 15:3938–46.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Ravandi F, O'Brien S, et al. (2010). Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 116:4422–9.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. (2012). Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670–7.
   PubMed Web of Science ®Google Scholar
• Kernytsky A, Wang F, Hansen E, et al. (2015). IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood 125:296–303.
   PubMed Web of Science ®Google Scholar
• Kuykendall JR. (2005). 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann Pharmacother 39:1700–9.
   PubMed Web of Science ®Google Scholar
• Li LH, Olin EJ, Buskirk HH, Reineke LM. (1970). Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Res 30:2760–9.
   PubMed Web of Science ®Google Scholar
• Oran B, Weisdorf DJ. (2012). Survival for older patients with acute myeloid leukemia: a population-based study. Haematologica 97:1916–24.
   PubMed Web of Science ®Google Scholar
• Oz S, Raddatz G, Rius M, et al. (2014). Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells. Nucleic Acids Res 42:e152.
   PubMed Web of Science ®Google Scholar
• Pleyer L, Stauder R, Burgstaller S, et al. (2013). Azacitidine in patients with WHO-defined AML – results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 6:32.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Santos FP, Garcia-Manero G. (2010). Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 7:433–44.
   PubMed Web of Science ®Google Scholar
• Rius M, Keller D, Brom M, et al. (2010). Vectorial transport of nucleoside analogs from the apical to the basolateral membrane in double-transfected cells expressing the human concentrative nucleoside transporter hCNT3 and the export pump ABCC4. Drug Metab Dispos 38:1054–63.
   PubMed Web of Science ®Google Scholar
• Rius M, Stresemann C, Keller D, et al. (2009). Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther 8:225–31.
   PubMed Web of Science ®Google Scholar
• Spratlin J, Sangha R, Glubrecht D, et al. (2004). The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10:6956–61.
   PubMed Web of Science ®Google Scholar
• Stein EM, Dinardo CD, Pollyea DA, et al. (2017). Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood 130:722–31.
   PubMed Web of Science ®Google Scholar
• Stresemann C, Lyko F. (2008). Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8–13.
   PubMed Web of Science ®Google Scholar
• Thepot S, Itzykson R, Seegers V, et al. (2014). Azacitidine in untreated acute myeloid leukemia: a report on 149 patients. Am J Hematol 89:410–6.
   PubMed Web of Science ®Google Scholar
• Tsai HC, LI, H, VAN, Neste L, Cai Y, Robert C, et al. (2012). Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21:430–46.
   PubMed Web of Science ®Google Scholar
• Tsukada Y, Fang J, Erdjument-Bromage H, et al. (2006). Histone demethylation by a family of JmjC domain-containing proteins. Nature 439:811–6.
   PubMed Web of Science ®Google Scholar
• Turcan S, Rohle D, Goenka A, et al. (2012). IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–83.
   PubMed Web of Science ®Google Scholar
• Unnikrishnan A, VO, ANQ, Pickford R, Raftery MJ, et al. (2018). AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo. Leukemia 32:900–10.
   PubMed Web of Science ®Google Scholar
• Visser O, Trama A, Maynadie M, et al. (2012). Incidence, survival and prevalence of myeloid malignancies in Europe. Eur J Cancer 48:3257–66.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen P, Wang J, et al. (2013). In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. Aaps J 15:242–9.
   PubMed Web of Science ®Google Scholar
• Yamane K, Toumazou C, Tsukada Y, et al. (2006). JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell 125:483–95.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. (2017). AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov 7:478–93.
   PubMed Web of Science ®Google Scholar
• Yen KE, Bittinger MA, Su SM, Fantin VR. (2010). Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29:6409–17.
   PubMed Web of Science ®Google Scholar
• Young JD, Yao SYM, Baldwin JM, et al. (2013). The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29. Mol Aspects Med 34:529–47.
   PubMed Web of Science ®Google Scholar